Aileron Therapeutics, Inc. (NASDAQ:ALRN – Get Free Report) saw a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 3,900 shares, a decline of 13.3% from the October 15th total of 4,500 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average trading volume of 40,100 shares, the days-to-cover ratio is presently 0.1 days.
Aileron Therapeutics Trading Down 1.9 %
Shares of NASDAQ:ALRN traded down $0.03 on Wednesday, hitting $1.55. The company’s stock had a trading volume of 909 shares, compared to its average volume of 38,384. Aileron Therapeutics has a 12 month low of $1.01 and a 12 month high of $3.40. The stock’s 50-day moving average is $1.44 and its two-hundred day moving average is $1.59.
Aileron Therapeutics (NASDAQ:ALRN – Get Free Report) last posted its quarterly earnings data on Friday, October 13th. The company reported ($0.40) EPS for the quarter. Equities analysts predict that Aileron Therapeutics will post -1.4 earnings per share for the current year.
Institutional Inflows and Outflows
Aileron Therapeutics Company Profile
Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.
- Five stocks we like better than Aileron Therapeutics
- Trading Stocks: RSI and Why it’s Useful
- 5 must-have next-gen technologies that institutions are buying
- How to Invest in Renewable Energy
- 3 intriguing late-week earnings plays for short-term traders
- How to Calculate Stock Profit
- Datadog is about to hit 52-week highs, and there’s more to come
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.